NasdaqGM:VCYTBiotechs
Veracyte (VCYT) Valuation Check After Strong Q3 Beat and Upgraded 2024 Revenue, Margin Guidance
Veracyte (VCYT) just delivered a stronger than expected third quarter, topping earnings and revenue forecasts and lifting its full year revenue and adjusted EBITDA margin guidance, a combination that tends to reset investor expectations fast.
See our latest analysis for Veracyte.
That upbeat guidance lands after a strong run, with the share price up around 37 percent on a 90 day basis and supported by a 67 percent three year total shareholder return. This suggests momentum is building even...